
Biotest AG
BIESFOTCHealthcare
$32.00
+$0.00(+0.00%)
Market Cap$1.6B
P/E Ratio—
52W High$32
52W Low$30.48
Biotest AG(BIESF)· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · BIESF · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.73B | $0.68B | $0.52B | $0.52B | $0.48B |
| Cost of Revenue | $0.50B | $0.40B | $0.39B | $0.43B | $0.35B |
| Gross Profit | $0.22B | $0.28B | $0.12B | $0.08B | $0.13B |
| Gross Margin %(computed) | 30.82% | 40.94% | 24.20% | 15.65% | 26.87% |
| Operating Expenses | |||||
| R&D Expenses | $0.06B | $0.07B | $0.05B | $0.05B | $0.06B |
| G&A Expenses | $0.04B | $0.03B | $0.03B | $0.03B | $0.03B |
| Total Operating Expenses | $0.13B | $0.14B | $0.13B | $0.13B | $0.13B |
| Operating Income | $0.09B | $0.14B | ($0.02B) | ($0.05B) | ($0.00B) |
| Operating Margin %(computed) | 13.01% | 20.96% | -3.22% | -9.13% | -0.27% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.04B | $0.02B | $0.01B | $0.01B |
| Income Before Tax | $0.05B | $0.11B | ($0.03B) | ($0.06B) | ($0.03B) |
| Income Tax Expense | $0.02B | ($0.02B) | $0.00B | $0.00B | $0.00B |
| Net Income | $0.03B | $0.13B | ($0.03B) | ($0.06B) | ($0.03B) |
| Net Margin %(computed) | 3.64% | 18.55% | -6.14% | -12.30% | -6.48% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.71 | $3.21 | $-0.80 | $-1.61 | $-0.79 |
| Wtd Avg Shares | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B |
| EBITDA | $0.12B | $0.18B | $0.02B | ($0.02B) | $0.01B |
| EBITDA Margin %(computed) | 16.58% | 26.61% | 4.79% | -3.55% | 2.87% |
数据来源:Financial Modeling Prep · 最后更新:2026-06-08 · EUR · B
深入了解Biotest AG
关于Biotest AG(BIESF)损益表
Biotest AG(BIESF)损益表数据来源于SEC Form 10-K及10-Q申报文件。2024财年,BIESF实现营收$0.73B,毛利润$0.22B(毛利率30.82%),净利润$0.03B(净利率3.64%)。
常见问题
BIESF · 4 问Biotest AG(BIESF)2024财年营收为$0.73B,同比up6.1%。
BIESF revenueBIESF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08